Sun Guihua, Cheng Ya-Wen, Lai Lily, Huang Tsui-Chin, Wang Jinhui, Wu Xiwei, Wang Yafan, Huang Yasheng, Wang Jinghan, Zhang Keqiang, Hu Shuya, Yang Ji-Rui, Yen Yun
Department of Molecular Pharmacology, Beckman Research Institute of The City of Hope, Duarte, CA, USA.
Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Oncotarget. 2016 Jan 26;7(4):3857-72. doi: 10.18632/oncotarget.6460.
To explore the role of miRNAs in colorectal cancers (CRC), we have deep sequenced 48 pairs of frozen CRC samples, of which 44 pairs produced high quality sequencing data. By using a combined approach of our bias reduction small RNA (smRNA) deep sequencing protocol and Illumina small RNA TruSeq method for sample bar coding, we have obtained data from samples of relatively large size with bias reduced digital profile results. This novel approach allowed us to validate many previously published results using various techniques to profile miRNAs in CRC tissues or cell lines and to characterize 'true' miRNA signatures highly expressed in colon/rectum (CR) or CRC tissues. According to our results, miR-21, a miRNA that is up-regulated in CRC, and miR-143, a miRNA that is down-regulated in CRC, are the two miRNAs that dominated the miRNA population in CR tissues, and probably are also the most important miRNAs in CRCs. These two miRNAs, together with the other eight miRNAs, miR-148a, -194, -192, 200b, -200c, -10b, -26a, and -145, with descending expressing levels, constituted the top 10 highly expressed miRNAs in CR/CRC. Using TaqMan miRNA qPCR, we detected the relative expression of some of the CRC miRNAs in 10 CRC cell lines, validated their dysregulation under cancer condition, and provided possible explanation for their dysregulation, which could be caused by APC, KRAS, or TP53 mutations. We believe these results will provide a new direction in future miRNA-related CRC development studies, and application of miRNAs in CRC diagnosis/prognosis, and therapy.
为了探究微小RNA(miRNA)在结直肠癌(CRC)中的作用,我们对48对冷冻CRC样本进行了深度测序,其中44对产生了高质量的测序数据。通过将我们的偏差减少小RNA(smRNA)深度测序方案与Illumina小RNA TruSeq方法相结合用于样本条形码编码,我们从相对较大规模的样本中获得了数据,且偏差减少后的数字图谱结果良好。这种新方法使我们能够利用各种技术验证许多先前发表的关于CRC组织或细胞系中miRNA谱分析的结果,并鉴定在结肠/直肠(CR)或CRC组织中高表达的“真正的”miRNA特征。根据我们的结果,miR-21(一种在CRC中上调的miRNA)和miR-143(一种在CRC中下调的miRNA)是在CR组织中占主导地位的两种miRNA,可能也是CRC中最重要的miRNA。这两种miRNA与其他8种miRNA,即miR-148a、-194、-192、200b、-200c、-10b、-26a和-145,按照表达水平从高到低排列,构成了CR/CRC中表达最高的前10种miRNA。使用TaqMan miRNA qPCR,我们检测了10种CRC细胞系中一些CRC miRNA的相对表达,验证了它们在癌症状态下的失调情况,并为其失调提供了可能的解释,这种失调可能是由APC、KRAS或TP53突变引起的。我们相信这些结果将为未来与miRNA相关的CRC发展研究以及miRNA在CRC诊断/预后和治疗中的应用提供新的方向。